OR12-1 Activity of Abiraterone Acetate in the management of Cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial.

BACKGROUND: More than 50% of adrenocortical carcinomas (ACC) in adults are associated with cortisol excess that makes tumor management challenging and has a negative impact on patient outcome. Abiraterone acetate (AA) is an irreversible inhibitor of the 17α-hydroxylase/C17, 20-lyase (CYP17 enzyme) t...

Descripción completa

Detalles Bibliográficos
Autores principales: Abate, Andrea, Basile, Vittoria, Berruti, Alfredo, Calabrese, Anna, Cosentini, Deborah, Ferrari, Vittorio Domenico, Grisanti, Salvatore, Laganà, Marta, Perotti, Paola, Pia, Anna, Puglisi, Soraya, Rossini, Elisa, Saba, Laura, Sigala, Sandra, Terzolo, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Adrenal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625183/
http://dx.doi.org/10.1210/jendso/bvac150.171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625183/
http://dx.doi.org/10.1210/jendso/bvac150.171

Ejemplares similares